MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation
European Journal of Neuroscience May 1, 2006 Christopher Bishop, Jennifer L. Taylor, Donald M. Kuhn et al. 63 citations
Abstract Chronic l ‐3,4‐dihydroxyphenylalanine (L‐DOPA) pharmacotherapy in Parkinson's disease is often accompanied by the development of abnormal and excessive movements known as dyskinesia. Clinical and experimental studies indicate that indirect serotonin agonists can suppress dyskinesia without affecting the efficacy of L‐DOPA. While the mechanism by which these effects occur is not clear,...
DOI: 10.1111/j.1460-9568.2006.04790.x (opens in new tab)
MDMA
Serotonin
Benserazide
Medial forebrain bundle
+8